Rapamycin extended average lifespan by 10–15% in marmosets, rat-sized monkeys, the study leader reports: almost all the animals have now died, and the team hopes to publish the final paper by early 2027
Rapamycin extended average lifespan by 10–15% in marmosets, rat-sized monkeys, the study leader reports: almost all the animals have now died, and the team hopes to publish the final paper by early 2027
In an interview released by Modern Healthspan on November 12, Adam Salmon, a professor at the University of Texas Health Science Center at San Antonio, discussed the results of a study that began in 2016. Nearly 70 marmosets received either rapamycin mixed into yogurt or the same yogurt without the drug.
Mice do not develop many of the age-related diseases that affect humans, Salmon explains. Monkeys do, but rhesus macaques can live to forty, so studying them would take decades. Marmosets live for an average of seven to nine years and develop heart, kidney, and joint disease as they age.
The marmosets were seven years old on average when the study began. By Salmon's estimate, this corresponds to a human age somewhere between the mid-fifties and early sixties. Rapamycin, a drug taken after organ transplantation, inhibits mTOR, a protein that regulates cell growth. The researchers chose it because it had extended lifespan in mice in study after study. The dose, about a milligram per kilogram of body weight per day, was selected to produce blood concentrations close to those in the mouse studies. Salmon considers this dose much higher than those being discussed for humans and would include a lower-dose group if he repeated the study.
Almost all the marmosets have died of natural causes, and those receiving rapamycin lived 10–15% longer on average. Salmon compares this increase with the early mouse studies, which found gains of a similar magnitude, and puts it in human terms: “For a human, 15% of average lifespan would be almost ten years.”
According to Salmon's observations, the effects are largely similar in males and females, and bodily functions begin to decline later in animals receiving rapamycin: their kidneys maintained baseline function for longer. Muscle findings from these marmosets are described in an Aging Cell paper published on November 6. Genes associated with inflammation become more active in muscle with age, but their activity was lower in six old marmosets receiving rapamycin than in six old marmosets receiving no drug.
The researchers found no sustained increase in blood glucose in the marmosets, either in measurements reflecting average levels over several months or in a glucose tolerance test. Long-term rapamycin treatment disrupts glucose metabolism in mice, and a 2012 study explains why. The mTOR protein is part of two complexes, mTORC1 and mTORC2. With prolonged treatment, rapamycin inhibits both, and without mTORC2, insulin is less effective at suppressing glucose production in the liver. Salmon believes the liver partly explains the difference between mice and marmosets: it accounts for 5–6% of body weight in mice and has a greater influence on glucose metabolism. In humans, it accounts for about 2,5%, and according to a 2019 review, the proportion in marmosets is closer to that in humans.
The most notable side effect, Salmon says, affected the joints and was discovered incidentally during tissue analysis. Adam Konopka's group at the University of Wisconsin examined knees from 65 marmosets and reported the findings in a preprint (a paper that has not been peer reviewed). Rapamycin did not change the overall severity of age-related osteoarthritis, but it increased calcium deposition in the meniscus and thinned the bone beneath the cartilage, particularly in females. In the same preprint, the researchers induced osteoarthritis in female mice by rupturing a knee ligament, and rapamycin worsened cartilage damage in these animals.
The final paper depends on the postmortem examinations of all the animals. The findings are being analyzed to answer the following question:
“Has rapamycin changed what they die from, does it protect against different causes of death, or does it simply delay death?”
Rapamycin serves as a proof of principle in this study, Salmon says: “targeting a pathway such as mTOR has the potential to treat aging.”